文献速递妇科

IMproving宫颈癌初筛与阴道镜分流试验:基线及1年随访的人乳头瘤病毒、细胞学与组织病理学结果

The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
PubMed 文献 · Am J Obstet Gynecol · 2021-04-20

该前瞻性多中心美国宫颈癌筛查试验纳入35263名25-65岁常规筛查女性,采用液体细胞学及两种高危HPV PCR检测,对异常者转诊阴道镜活检。基线高危HPV、HPV16、HPV18患病率分别为15.1%、3.1%、1.4%,HPV16阳性者CIN3+的1年累积风险为16.9%,HPV阴性者仅0.06%。

要点

  • 基线高危HPV患病率15.1%,HPV16为3.1%,HPV18为1.4%。
  • HPV16阳性女性CIN3+的1年累积风险为16.9%。
  • HPV阴性女性CIN3+的1年累积风险最低,为0.06%。

核心结论

  • 该大型美国筛查人群的当代年龄别HPV、细胞学异常及CIN患病率为医疗政策、筛查项目及实验室和临床医生提供了基准。

研究设计与样本

  • 前瞻性、多中心、美国宫颈癌筛查试验,共纳入35263名25-65岁常规筛查女性。
  • 行液体细胞学及两种高危HPV PCR检测,异常者及随机阴性子集转诊阴道镜活检,未达终点者进入1年随访。

主要发现

  • ASC-US及以上细胞学异常患病率为6.5%,ASC-US以上为3.2%。
  • 基于cobas HPV检测的高危HPV、HPV16、HPV18患病率分别为15.1%、3.1%、1.4%。
  • 细胞学异常和HPV阳性率均随年龄增长而下降。
  • 转诊阴道镜活检女性中CIN2+和CIN3+患病率分别为8.8%和3.6%。
  • HPV16阳性女性CIN3+基线和1年累积风险分别为13.6%和16.9%,HPV阴性女性1年累积风险为0.06%。

临床怎么用

  • 可将报告中HPV型别别及细胞学年龄别患病率作为筛查咨询和风险分层的参考基准。
  • HPV16阳性者CIN3+短期风险较高,需密切随访或及时阴道镜评估。
  • HPV阴性者1年内CIN3+风险极低,可支持延长筛查间隔的决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: An increase in human papillomavirus test volumes is expected in the near future because human papillomavirus-based screening protocols are expected to become more widely adopted. OBJECTIVE: The IMproving Primary Screening And Colposcopy Triage trial, a prospective, multicenter, US-based cervical cancer screening trial, was conducted to obtain US Food and Drug Administration approvals for the new, high-throughput cobas human papillomavirus (cobas HPV) test for use on the cobas 6800/8800 Systems (cobas HPV) for detecting cervical precancerous and cancerous cells (cervical intraepithelial neoplasia of grade 2 or worse and grade 3 or worse). Here, the baseline demographics, human papillomavirus test results, cervical cytology, and histopathologic results are presented. In addition, the baseline and 1-year risks of cervical intraepithelial neoplasia grade 2 or worse and grade 3 or worse associated with the human papillomavirus results are reported. STUDY DESIGN: In total, 35,263 women aged between 25 and 65 years undergoing routine screening were enrolled; liquid-based cytology and 2 polymerase chain reaction-based tests for high-risk human papillomavirus were performed. Women with abnormal Papanicolaou cytology, women positive for high-risk human papillomavirus by either of the 2 human papillomavirus tests, and a random subset of women negative according to the Papanicolaou cytology and the 2 human papillomavirus tests were referred for a colposcopy and cervical biopsy. Women who did not meet the study endpoint were eligible for the 1-year follow-up study phase. Verification bias-adjusted cervical disease prevalence and risks and 95% confidence intervals were computed. RESULTS: The prevalence of atypical squamous cells of undetermined significance and worse than atypical squamous cells of undetermined significance cytology were 6.5% and 3.2%, respectively. Prevalence of high-risk human papillomavirus, human papillomavirus 16, and human papillomavirus 18 based on the new cobas HPV test were 15.1%, 3.1%, and 1.4%, respectively. Both cytologic abnormalities and human papillomavirus positivity declined with increasing age. Among women who had a colposcopy and biopsy, the prevalence of cervical intraepithelial neoplasia grade 2 or worse and grade 3 or worse were 8.8% and 3.6%, respectively. The baseline and 1-year cumulative risks for cervical intraepithelial neoplasia grade 3 or worse were 13.6% and 16.9%, respectively, among women who tested positive for human papillomavirus 16. Women who tested negative for human papillomavirus had the lowest 1-year cumulative risk for cervical intraepithelial neoplasia grade 3 or worse (0.06%). CONCLUSION: The contemporary, age-specific prevalence of human papillomaviruses (including human papillomavirus 16 and 18), cytologic abnormalities, and cervical intraepithelial neoplasia in a large, US-based cervical cancer screening population provides benchmarks for healthcare policies, screening programs, and for laboratories and clinicians.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Safaeian M, Wright TC, Stoler MH, et al. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase. Am J Obstet Gynecol. 2021. PMID: 33852886. doi:10.1016/j.ajog.2021.03.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。